BACKGROUND: Multiple studies have compared coronary artery bypass graft (CABG) with percutaneous coronary interventions (PCI) for coronary revascularization. There is considerable evidence that adherence to medical therapy can affect the outcomes of therapeutic interventions. However, the long-term influence of compliance with recommended medical therapy on the comparative outcomes of CABG versus PCI remains to be defined.
i t is well recognized that medication adherence can vary widely among patient populations and medical conditions 1 and that such variance can have a major effect on clinical outcome. 2, 3 Specifically, appropriate medical therapy is known to affect long-term outcomes of patients undergoing coronary artery revascularization (CR), whether surgically or interventionally. 4, 5 Similarly, there are probably very few therapeutic choices that have been as well studied as that between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) for the treatment of coronary artery disease. 6, 7 What has been remarkably absent from prior analyses, however, has been the effect of adherence to evidencebased medical therapy on the relative outcome of CABG versus PCI in patients with advanced coronary artery disease. Because patient selection and behavior in randomized, clinical trials may not reflect actual clinical practice, 8 we investigated the effect of adherence to guideline-driven medical therapy on the outcomes of CABG versus PCI in a prospective, multicenter, community-based registry.
MethOds
As published previously, 9, 10 the CARE registry (Coronary Artery Revascularization Evaluation) was a multicenter registry recording data on consecutive patients undergoing CR procedures from 8 community hospitals. There were no prespecified selection criteria, and patients were treated according to physician preference. Data were collected locally and returned to a central repository where they were entered into a proprietary database. The protocol was approved by the Institutional Review Board for North Texas at Medical City Dallas Hospital with a waiver of consent.
Procedures were performed and data were collected over a 6-month period from February 1, 2004 , until July 31, 2004 . All collected data were subjected to quality checks and validation tests. Follow-up was performed for between 12 and18 months and again starting in 2009, after which the database was locked. Follow-up included Social Security Death Index validation of all mortalities, hospital and physician inquiries, and letters and telephone calls to patients. Detailed medication history was taken from each patient at both the midterm (18 months) and late (5-7 years) follow-up. Patient responses concerning antiplatelet therapy, therapy with lipid-lowering agents (LLAs), and β-blocker treatment were analyzed. Although the vast majority of single antiplatelet regimens consisted of acetylsalicylic acid (ASA) and the most common LLAs were statins, no distinction was made in this analysis in terms of specific agents or dosages within the general categories. Patients with a diagnosis of ST-segment-elevation myocardial infarction or status listed as salvage were deleted from the data set for this analysis. The primary end point was major adverse cardiac events (MACEs), which were mortality, nonfatal myocardial infarction (MI), and any repeat revascularization procedure.
Data were summarized and compared by use of χ 2 statistics for discrete variables and t test or ANOVA for continuous data. Propensity matching with 18 preoperative risk parameters (online-only Data Supplement Tables I-III) and accounting for nesting of patients in hospitals was used to minimize the selection bias introduced by clinician selection of CABG or PCI. The scores were put through a 1-to-1 greedy matching algorithm that produced 1-equivalent data sets for PCI and CABG patients with ≥5 years of follow-up. Survival curves were derived with Kaplan-Meier methods with equality of distribution tested by the log-rank test, and hazard ratios (HRs) and cumulative hazards were calculated from the Cox proportional hazard model. Missing data on medications were dropped from analysis because there was no reliable mechanism to impute when the reasons for nonadherence are not known (online-only Data Supplement Table IV ). All statistical calculations used SAS 9.4 (SAS Institute, Cary, NC).
results
The study sample consists of 973 CABG and 2255 PCI patients. As noted in the Table, clinical characteristics were different in many respects between the groups, with a higher incidence of smoking, cerebral and peripheral vascular disease, triple-vessel disease, reduced ejection fraction, and nonelective status in the surgical group and a higher incidence of prior procedures in the clinical Perspective What is new?
• Multiple studies have compared coronary artery bypass graft (CABG) with percutaneous coronary interventions (PCI) for coronary revascularization.
There is considerable evidence that adherence to medical therapy can affect the outcomes of therapeutic interventions. However, the long-term influence of compliance with evidence-based medical therapy on the comparative outcomes of CABG versus PCI remains to be defined. • Here, we explore the effect of medication adherence on the long-term comparative outcomes of CABG versus PCI in a multicenter clinical registry.
What are the clinical implications?
• Regardless of revascularization strategy, patients who adhere to appropriate medical therapy have a significantly improved major adverse cardiac eventfree survival. • Among well-matched patients who are compliant with recommended medical therapy, there may not be a clinical benefit for either PCI or CABG. • Among well-matched patients who are not compliant with recommended medical therapy, there is a marked benefit for CABG over PCI. • Results warrant confirmation in larger, more contemporary databases. If corroborated, a patient's ability to adhere to medical regimen may affect the selection of optimal therapy for patients requiring coronary revascularization.
interventional group. Follow-up was 67±25.8 months (median, 84 months) for CABG patients and 61.8±28.6 months (median, 79.4 months) for the PCI group. When analyzed within groups, both antiplatelet medication and LLA therapy appeared to have a profound effect on MACE-free survival. Because ASA is a recommended treatment for all CABG patients without specific contraindications, patients who were prescribed ASA at discharge and were reported to be on the drug at all follow-up points (optimal medical therapy [OMT]) were compared with those who either had not been prescribed ASA at discharge or were not on the drug at any point during follow-up (non-OMT). Figure 1A shows a dramatic difference in late MACE-free survival favoring appropri-ate medical therapy (P=0.001). Similarly, CABG patients who left the hospital on LLA therapy and were still on the drug at all follow-up points enjoyed a markedly improved MACE-free survival compared with those who at any point were not on the medication (P=0.001; Figure 1B ). Although β-blocker prescription at hospital discharge is a National Quality Forum standard for CABG patients, long-term β-blocker treatment is generally clinically based, despite emerging evidence of long-term benefit. 5 We therefore examined the effect of β-blocker therapy on long-term outcome and once again demonstrated a marked difference in event-free survival (P=0.001; Figure 1C ). Because of the complex nature of medication adherence and the fact that our data do not permit us to Tables V and VI) . Similar analyses were performed for the PCI group. Because OMT antiplatelet therapy, regardless of stent type, would require both ASA and a P2Y inhibitor at the time of discharge and continuation of ASA indefinitely thereafter, 11, 12 any patient who did not receive prescriptions for both at the time of discharge or who was not on ASA at any point during follow-up was considered non-OMT. The difference in MACE-free survival between groups was dramatic (P=0.001; Figure 2A ). Similarly, because antilipid treatment is recommended for all patients, a survival benefit was demonstrated that increased over time (P=0.001; Figure 2B ). Although β-blocker therapy after successful PCI has not been studied in randomized, controlled trials, in this study population, there was a MACEfree survival benefit for OMT β-blocker therapy (P=0.001; Figure 2C ). Cox regression of factors associated with MACEs in PCI patients identified that lack of adherence to either appropriate antiplatelet therapy (double antiplatelet regimen at discharge and ASA on follow-up) or LLA treatment was strongly associated with MACEs (for antiplatelet therapy: HR=2.87, 95% CL, 2.26-3.66, P<0.001; for LLA therapy: HR=1.99, 95% CL, 1.58-2.51, P<0.001). Similarly, adherence to both was predictive of MACEs (HR=2.79; 95% CL, 2.12-3.67; P<0.001; online-only Data Supplement Tables VII and VIII) .
Because the role of long-term β-blocker therapy in CABG and PCI patients has not been fully elucidated, we defined the OMT group as those patients who were taking both antiplatelet and LLA therapy OMT and examined the effect that treatment had on the relative outcomes for CABG versus PCI. Among patients who were not following the appropriate antiplatelet/LLA protocol, CABG patients enjoyed a much-enhanced MACE-free survival compared with those who underwent PCI (P=0.001; Figure 3A ). However, among those on OMT, the benefit of CABG appeared to be considerably less (P=0.048; Figure 3B ). Because CABG and PCI patients had different risk profiles, matched groups of patients were created in each group (online-only Data Supplement Tables  I and II ). Matched non-OMT patients still demonstrated a MACE-free survival benefit for CABG (P=0.001; Figure 4A ). However, among matched patients taking OMT, there was no difference in outcome between CABG and PCI (P=0.574; Figure 4B ). When the entire study popula-tion was examined, with both approaches to revascularization (CABG versus PCI) and medication (OMT versus non-OMT) entered into the model, Cox regression demonstrated that nonadherence to both OMT and PCI was associated with an increased incidence of MACEs. However, the association of OMT was in fact stronger than that for the interventional strategy (non-OMT: HR=2.79, 95% CL, 2.19-3.54, P<0.001; PCI versus CABG: HR=1.68, 95% CL, 138-2.04, P<0.001; onlineonly Data Supplement Table IX) .
Because propensity score matching resulted in groups that were smaller than the original cohorts, we further performed Cox regression of the entire patient population with propensity score entered into the model to look for interactions between choice of therapy (PCI versus CABG) and adherence or nonadherence to OMT. For nonadherent patients, the point estimates show a ORIGINAL RESEARCH ARTICLE 1243 benefit for CABG (HR for PCI versus CABG=1.88; 95% CL, 1.49-2.38), whereas for adherent patients, we were not able to demonstrate a similar benefit because of the wider confidence intervals with smaller numbers in the group (HR, 1.82; 95% CL, 0.95-3.51).
discussiOn
Compliance with evidenced-based medical therapies is a complex construct of physician and patient behavior. It is well known that clinical practice guidelines frequently fail to change physician behavior. 13, 14 Even documented knowledge of the recommendations does not appear to necessarily influence performance. 15 On the other hand, patient adherence rates to prescribed regimens are typically higher among patients with acute rather than chronic conditions and tend to drop rather dramatically after the 6 months of therapy. 16, 17 Even among clinical trial participants, adherence rates have been reported in the 43% to 78% range among patients receiving treat- Figure 3 . survival free from major adverse cardiac events (Maces) in unmatched patients following or not following an optimal antiplatelet and lipid-lowering regimen.
A, Survival free from MACEs among unmatched patients who underwent coronary artery bypass graft surgery (CABG) vs patients who underwent percutaneous coronary intervention (PCI) who were not following an optimal antiplatelet and lipid-lowering regimen (optimal medical therapy [OMT]). B, Survival free from MACEs among unmatched patients who underwent CABG vs PCI who were following an optimal antiplatelet and lipid-lowering regimen (OMT). Figure 4 . survival free from major adverse cardiac events (Maces) in matched patients following or not following an optimal antiplatelet and lipid-lowering regimen.
A, Survival free from MACEs among matched patients who underwent coronary artery bypass graft surgery (CABG) vs patients who underwent percutaneous coronary intervention (PCI) who were not following an optimal antiplatelet and lipid-lowering regimen (optimal medical therapy [OMT]). B, Survival free from MACEs among matched patients who underwent CABG versus PCI who were following an optimal antiplatelet and lipid-lowering regimen (OMT). ment for chronic conditions. 1 It is therefore essential to evaluate the effect of therapeutic options in a context that reflects actual clinical practice. As an observational study, the CARE registry was not designed to delineate the reasons behind medical decisions or the optimal therapeutic potential of those choices but rather to define the outcomes of medical care as it is actually delivered. The available data do not permit an analysis of reasons for the selection of CABG or PCI, nor do they suggest the causes of compliance or noncompliance with guideline-directed medical therapy. However, reasonably long-term follow-up of an all-comer cohort of patients undergoing CR has clearly demonstrate several important points:
1. Regardless of revascularization strategy, patients who adhere to appropriate medical therapy have a significantly improved MACE-free survival. 2. Among well-matched patients who are adherent to recommended medical therapy, there may not be a clinical benefit for either PCI or CABG. 3. Among well-matched patients who are not adherent to recommended medical therapy, there is a marked benefit for CABG over PCI. These findings, however, are based on retrospective data derived from subgroup analyses of limited numbers of patients and can best be viewed as hypothesis generating.
Although these findings clearly warrant confirmation in other larger cohorts of patients, they are consistent with those of the 5-year follow-up from the SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery), 4 and their implications are far-reaching from both a clinical and a scientific point of view. Because CABG seeks to address downstream perfusion and PCI directly addresses the critical obstructing lesions, the benefits of CABG may be less subject to the need for appropriate medical therapy. Arterial grafting may further enhance the benefits of CABG in nonadherent patients, 18 perhaps in the case of the internal mammary artery by nourishing downstream circulation with enhanced delivery of nitric oxide. 19, 20 Therefore, among patients who might be anatomically suitable for either approach, for those who are unlikely to accept the rigors of careful medical therapy, CABG may be preferable to PCI. Because there is a spectrum of risk that people are willing to accept, including the risk of death, to avoid daily medication for cardiovascular prevention, 21 surgery may provide the most reasonable long-term benefit. On the other hand, in an anatomically similar situation, if the patient is likely to carefully follow his or her medical regimen, PCI may be a more appropriate option. Indeed, many patients will prefer multivessel PCI to CABG even if the 1-year risks of death and repeat procedures far exceed those of CABG. 22 Careful medical follow-up thus becomes critical in caring for such patients.
From the perspective of outcomes research, these findings suggest that any long-term comparison of these 2 therapeutic approaches cannot be fully or appropriately evaluated without information on medication adherence. Although the literature is replete with such studies, 7, 8, 23 the effect of adherence to appropriate medical therapy on comparative outcomes has not been previously defined. The results of this observational study suggest both a dramatic effect of medication adherence on the long-term outcomes of each approach and a differential influence when these 2 approaches to CR are compared. These findings strongly suggest that future investigations of different approaches to CR should directly address the issue of adherence to OMT in the interpretation of findings.
liMitatiOns As a retrospective, multicenter, observational study, patient groups may reflect multiple potential treatment biases. Although propensity score matching was used to attempt to account for differences between groups and multivariable modeling was used to adjust for potentially associated risk factors, there may be patient and other factors for which statistical modeling cannot fully account. Medication history was based on patient recall, with its well-known limitations, 1 although this been found to be effective, 24, 25 with no approach considered the gold standard. 26, 27 Moreover, we do not know the status of medical therapy between discharge and each of the 2 follow-up periods. Therefore, patient "per OMT" adherence may have been overestimated. Because we did not collect information on the rationale for treatment, patients not taking medications may have had contraindications of which we were not aware. Indeed, contraindications or intercurrent disease states that may have necessitated the cessation of medication may have affected the primary study outcome (MACE-free survival) and thereby biased the study, although there is no a priori reason to believe that it would necessarily bias one group more than the other, especially among matched patients. Stroke data were not available in this study. The initial study reported a relative low incidence of periprocedural stroke (0.1% for PCI versus 0.7% for CABG; P=0.003) 9 ; however, long-term outcomes suggest a higher incidence of stroke in CABG patients. 28 How this might be influenced by compliance with medical therapy remains a fruitful area for further study. Not all patients were able to be provide complete information on all medications. Although it may have been reasonable to assume that if a patient did not provide information on a medication, then he or she was not taking it, we elected a conservative approach of deleting that missing information from the analyses, thereby assuming that the 80% to 90% completed responses were best reflective of the study population. The absence of benefit for CABG versus PCI in the patients ORIGINAL RESEARCH ARTICLE 1245 ostensibly following OMT must be viewed with caution. Although the signal of benefit for CABG appears to different in the adherent versus the nonadherent patients, especially among propensity-matched groups, results should not be interpreted to conclude that there is no benefit for CABG in these patients but rather should be viewed as hypothesis generating that adherence to medical therapy may have an effect on the relative MACE-free survival benefit of CABG versus PCI, a hypothesis that warrants further testing in a larger, more contemporary patient population. Lastly, although the median follow-up for this study was 7 years, the implications of lifelong medical therapy for cardiovascular disease are controversial and require more careful, longer-term studies. 29 
cOnclusiOns
In the current era of CR, long-term results of a multicenter, community-based registry demonstrate that adherence to recommended medical therapies can have a profound effect on mortality and associated MACEs. This effect may be more compelling in the PCI than in the CABG patient population and may even be more important than choice of revascularization strategy itself. Knowledge of the relative effect of medication adherence can be extremely important in clinical decision making and should be addressed in all future comparative studies of CR strategies.
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